CROSSJECT overview

Press Release Dijon, FRANCE, February 6, 2025 –0730h (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces, in accordance with the agreement entered into with Heights in December 2024, the completion of the amendments of the terms and conditions of the bonds issued to an entity affiliated to...

Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France) Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company preparing to commercialize its epilepsy rescue therapy ZEPIZURE®, has successfully concluded a surveillance audit of its manufacturing sites, delivering new evidence its supply chain is ready to move ZEPIZURE®...

Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025 Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafter Crossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that year Dijon, France, October 22 2024 (07:30 CET) - Crossject...

Dijon, France, 17 September, 2024 - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®, will report its financial results for the six months ended June 30, 2024, as scheduled on Monday, September 23. In addition, at 18:00 CET that day, CEO Patrick Alexandre will provide a commentary on the company’s strategic priorities during a webcast and be available for...

Dijon, France, July 15 th 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE® , its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces it will attend the H.C. Wainwright 26th Annual Global Investment Conference, taking place in New York September 9-11, 2024. About Crossject Crossject SA (Euronext: ALCJ;...

Key contribution to the acceleration of the development of ZENEO® Epinephrine Financial support includes mainly grants, as well as subsidized loans France 2030 Plan dedicated to supporting French companies demonstrating outstanding growth and innovation potential Dijon, France, July 10 th , 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE® , its emergency treatment for the management of...